We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

RBC Capital analyst Gregory Renza maintained a Buy rating on aTyr Pharma (ATYR – Research Report) yesterday and set a price target of $16.00.

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cartesian Therapeutics (RNAC – Research Report) ...

According to the latest study from BCC Research, "Technical Textiles: Global Markets," is expected to grow from $213.8 billion in 2024 to $284.0 billion by the end of 2029, at a compound annual growth ...

River Road Asset Management reduced its stake in Amgen by 15.7% in Q4, selling 7,606 shares. Several other hedge funds also ...